BofA analyst Tim Anderson lowered the firm’s price target on Aardvark Therapeutics (AARD) to $25 from $26 and keeps a Buy rating on the shares. The firm updated its model for Q2 results and to account for a delay in launch timing assumptions, partly offset by a potentially larger addressable patient population, notes the analyst, who also rolls forward the firm’s base valuation year from 2025 to 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics Advances Clinical Trials and Financials
- Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital
- Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)
- Buy Rating for Aardvark Therapeutics, Inc. Driven by Promising ARD-201 Obesity Treatment Potential
- Aardvark Therapeutics Reveals Promising Preclinical Data for ARD-201